Influenza: Old and new threats

Nature Medicine

Volumn 10, Issue 12S, 2004, Pages S82-S87

  Palese, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; SMALL INTERFERING RNA; VIRULENCE FACTOR; VIRUS PROTEIN; VIRUS SIALIDASE; ZANAMIVIR;

AMINO ACID SEQUENCE; EPIDEMIC; FOOD AND DRUG ADMINISTRATION; GENE CONSTRUCT; GENETIC ENGINEERING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA; INFLUENZA VIRUS; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS MUTATION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANIMALS; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HUMANS; IMMUNITY, NATURAL; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; VACCINES; ZOONOSES;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS; RNA VIRUSES; VARIOLA VIRUS;

EID: 10944240992     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1141     Document Type: Review

References (43)

1. Hayden, F. & Palese, P. Influenza Virus. in Clinical Virology (ed. Richman, D.D.) 891-920 (Churchill Livingstone, New York, 1997).
2. Basler, C. & Palese, P. Influenza Viruses. in Encyclopedia of Molecular Medicine (ed. Creighton, T.) 1741-1747 (John Wiley and Sons, New York, 2002).
3. Fodor, E. et al. Rescue of influenza A virus from recombinant DNA. J. Virol. 73, 9679-9682 (1999).
4. Neumann, G. et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA 96, 8804-8806 (1999).
5. Taubenberger, J.K., Reid, A.H., Janczewski, T.A. & Fanning, T.G. Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356, 1829-1839 (2001).
6. Kawaoka, Y., Krauss, S. & Webster, R.G. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J. Virol. 63, 4603-4608 (1989).
7. Lipatov, A.S. et al. Influenza: Emergence and control. J. Virol. 78, 8951-8959 (2004).
8. Nakajima, K., Desselberger, U. & Palese, P. Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950. Nature 274, 334-339 (1978).
9. Klenk, H.D. & Rott, R. The molecular biology of influenza virus pathogenicity. Adv. Virus Res. 34, 247-281 (1988).
10. Tumpey, T.M. et al. Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc. Natl. Acad. Sci. USA 101, 3166-3171 (2004).
11. Kash, J.C. et al. Global host immune response: Pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus. J. Virol. 78, 9499-9511 (2004).
12. Kobasa, D. et al. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature431, 703-707 (2004).
13. Basler, C.F. et al. Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proc. Natl. Acad. Sci. USA 98, 2746-2751 (2001).
14. Geiss, G.K. et al. Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: The role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc. Natl. Acad. Sci. USA99, 10736-10741 (2002).
15. Seo, S.H., Hoffmann, E. & Webster, R.G. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat. Med. 8, 950-954 (2002).
16. Hatta, M., Gao, P., Halfmann, P. & Kawaoka, Y. Molecular basis for high virulence of Hong Kong H5N1 influenza viruses. Science 293, 1773-1775 (2001).
17. Dowdle, W.R. Influenza A virus recycling revisited. Bull. World Health Organ. 77, 820-826 (1999).
18. Zamarin, D. & Palese, P. Influenza virus: Lessons learned. in International Kilmer Conference (eds Kowalski, J.B. & Morissey, J.B.) (Polyscience Publications, Station St. Martin, Laval, Quebec, Canada, in the press).
19. Katz, J.M. The impact of avian influenza viruses on public health. Avian Dis. 47, 914-920 (2003).
20. Li, K.S. et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430, 209-213 (2004).
21. Webby, R.J. & Webster, R.G. Are we ready for pandemic influenza? Science 302, 1519-1521 (2003).
22. Hatta, M. & Kawaoka, Y. The continued pandemic threat posed by avian influenza viruses in Hong Kong. Trends Microbiol. 10, 340-344 (2002).
23. Shortridge, K.F. Pandemic influenza: A zoonosis? Semin. Respir. Infect. 7, 11-25 (1992).
24. Profeta, M.L. & Palladino, G. Serological evidence of human infections with avian influenza viruses. Arch. Virol. 90, 355-360 (1986).
25. Hay, A., Wolstenholme, A., Skehel, J. & Smith, M. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4, 3021-3024 (1985).
26. Monto, A.S. & Arden, N.H. Implications of viral resistance to amantadine in control of influenza A. Clin. Infect. Dis. 15, 362-367 (1992).
27. Palese, P. & Compans, R.W. Inhibition of influenza virus replication in tissue culture by 2-deoxy- 2, 3-dehydro-N-trifluoroacetylneuraminic acid (FANA): Mechanism of action. J. Gen. Virol. 33, 159-163 (1976).
28. Mendel, D.B. et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42, 640-646 (1998).
29. Colman, P.M. A novel approach to antiviral therapy for influenza. Antimicrob. Agents Chemother. 44, 17-22 (1999).
30. Kiso, M. et al. Resistant influenza A viruses in children treated with oseltamivir. A descriptive study. Lancet364, 759-765 (2004).
31. Carr, J. et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infec- tivity and replicative ability in vivo. Antiviral Res. 54, 79-88 (2002).
32. Tumpey, T.M. et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc. Natl. Acad. Sci. USA 99, 13849-13854 (2002).
33. Ge, Q. et al. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA 101, 8676-8681 (2004).
34. Tompkins, S.M., Lo, C-Y., Tumpey, T.M. & Epstein, S.L. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA 101, 8682-8686 (2004).
35. Kilbourne, E.D. et al. Related studies of a recombinant influenza virus vaccine. I. Derivation and characterization of virus and vaccine. J. Infect. Dis. 124, 449-462 (1971).
36. Hoffmann, E., Neumann, G., Hobom, G., Webster, R.G. & Kawaoka, Y. “Ambisense” approach for the generation of influenza A virus: Vrna and mRNA synthesis from one template. Virology 267, 310-317 (2000).
37. Talon, J. et al. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc. Natl. Acad. Sci. USA 97, 4309-4314 (2000).
38. Kemble, G. & Greenberg, H. Novel generations of influenza vaccines. Vaccine 21, 1789-1795 (2003).
39. Palese, P. & Garcia-Sastre, A. Influenza vaccines: Present and future. J. Clin. Invest. 110, 9-13 (2002).
40. Swayne, D.E. et al. Recombinant paramyxovirus type 1-avian influenza-H7 virus as a vaccine for protection of chickens against influenza and Newcastle disease. Avian Dis. 47, 1047-1050 (2003).
41. Taubenberger, J.K. & Palese, P. The origin and virulence of the 1918 “Spanish” influenza virus. in Contemporary Topics in Influenza Virology (ed. Kawaoka, Y.) (Horizon Scientific Press, Wymondham, Norfolk, UK, in the press).
42. Glezen, W.P. Emerging infections: Pandemic influenza. Epidemiol. Rev. 18, 64-76 (1996).
43. Reid, A.H., Taubenberger, J.K. & Fanning, T.G. The 1918 Spanish influenza: Integrating history and biology. Microbes Infect. 3, 81-87 (2001).